MedTrace Logo

Study of Arginine Butyrate and Ganciclovir/Valganciclovir in EBV(+) Lymphoid Malignancies

NCT00917826 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 1

Last updated 2011-08-01

No results posted yet for this study

Summary

The purpose of this study is to assess whether administration of Arginine Butyrate + ganciclovir/valganciclovir for up to three 21-day cycles is tolerable, and results in partial or complete responses in patients with EBV(+) lymphoid malignancies.

Conditions

  • EBV Lymphomas
  • Lympho-proliferative Diseases

Interventions

DRUG

Arginine Butyrate

1,000 mg/kg/day administered IV over 24 hours/day for 5 days (Days 1-5 of each 21 day cycle)

DRUG

Ganciclovir

5 mg/kg administered IV over 1 hour (Days 1-5 of each 21 day cycle)

DRUG

Valganciclovir

900 mg BID for 16 days (Days 6-21 of each 21 day cycle)

Sponsors & Collaborators

  • Boston University

    collaborator OTHER

  • HemaQuest Pharmaceuticals Inc.

    lead INDUSTRY

Principal Investigators

  • Adam Lerner, M.D. · Boston University School of Mediciine

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
3 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-09-30
Primary Completion
2009-09-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00917826 on ClinicalTrials.gov